Narayana Hrudayalaya Limited
Narayana Hrudayalaya Limited provides medical and healthcare services in India and the Cayman Islands. It operates through the Medical and Healthcare Related Services; and Others segments. The company offers oncology, anesthesiology, audiology, blood bank, oncoplastic surgery, cardiac surgery, cardiology, clinical genetics, clinical immunology, clinical nutrition and dietetics, clinical psychology, congenital adult heart disease, cosmetology, cranio-maxillofacial surgery, critical care medicine, dental, dermatology, pediatrics, diabetology, ENT, emergency medicine, endocrinology, family medicine, general and GI surgery, general medicine and surgery, geriatric medicine, gynecology, hematology, headache and facial pain management, transplant, infectious diseases, neurology, radiology, hepatobiliary surgery, gastroenterology, minimal access GI and bariatric surgery, neonatology, nephrology, neuro-otology, neuro-rehabilitation, neurosurgery and spine surgery, and nuclear medicine services. It also provides ophthalmology, orthopedics and joint replacement, pain management and palliative care, pathology, perinatology and fetal intervention, physical medicine and rehabilitation, physiotherapy and physical rehabilitation, plastic surgery, psychiatry, pulmonology, reproductive medicine, rheumatology, renal science, speech and swallow rehabilitation, spine surgery, thoracic and vascular surgery, ultrasonology, urology, and other services. In addition, the company acquires, owns, and operates hospitals, clinics, health centers, diagnostic centers, and nursing homes. Further, it provides health insurance, consultancy services in the field of healthcare and hospitals, and IT services related to healthcare. Additionally, the company engages in investment activities; and develops software related to the healthcare industry. Narayana Hrudayalaya Limited was incorporated in 2000 and is headquartered in Bengaluru, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Strong 5-year net profit CAGR of 44.3%
Concerns0
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ3.59 K Cr | β | βΉ431.00 Cr | β | β | 19.7% | 9.9% | 1.4% |
| Mar 2024 | βΉ3.27 K Cr | β | βΉ425.00 Cr | β | β | 23.1% | 10.2% | 59.8% |
| Mar 2023 | βΉ2.96 K Cr | β | βΉ266.00 Cr | β | β | 18.1% | 22.9% | 98.5% |
| Mar 2022 | βΉ2.41 K Cr | β | βΉ134.00 Cr | β | β | 10.9% | 45.7% | -269.6% |
| Mar 2021 | βΉ1.66 K Cr | β | βΉ-79.00 | β | β | -7.3% | -26.1% | -216.2% |
| Mar 2020 | βΉ2.24 K Cr | β | βΉ68.00 Cr | β | β | 5.8% | 7.8% | 36.0% |
| Mar 2019 | βΉ2.08 K Cr | β | βΉ50.00 Cr | β | β | 4.3% | 12.4% | -13.8% |
| Mar 2018 | βΉ1.85 K Cr | β | βΉ58.00 Cr | β | β | 5.2% | 12.3% | -38.9% |
| Mar 2017 | βΉ1.65 K Cr | β | βΉ95.00 Cr | β | β | 9.0% | 12.0% | 66.7% |
| Mar 2016 | βΉ1.47 K Cr | β | βΉ57.00 Cr | β | β | 6.0% | 12.4% | 171.4% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 3,746 |
| Total Expenses | 3,006 |
| EBIT / Operating Profit | 740 |
| OPM % | 20% |
| Other Income | 149 |
| Finance Costs | 106 |
| Depreciation & Amortisation | 182 |
| Profit Before Tax | 601 |
| Tax % | - |
| Net Profit / PAT | 464 |
| EPS (βΉ) | 22.74 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Narayana Hrudayalaya Limitedthis co. | βΉ38.57 K Cr | βΉ3.59 K Cr | 83.00 | 16.56 | 54.03 | 9.9% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |